Clinical Trial Detail

NCT ID NCT03215264
Title Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

colorectal cancer

Therapies

Entinostat + Hydroxychloroquine + Regorafenib

Age Groups: adult senior

No variant requirements are available.